Intravenous nesiritide in acute heart failure

Area of Science:

• Cardiology
• Pharmacoeconomics
• Health Services Research

Background:

• Congestive heart failure (CHF) is a significant cause of hospitalization and healthcare expenditure.
• Nesiritide is a natriuretic peptide used in managing acute decompensated CHF.
• Understanding the economic and clinical impact of nesiritide is crucial for treatment guidelines.

Purpose of the Study:

• To evaluate the comparative effectiveness of nesiritide versus usual care in patients with decompensated CHF.
• To assess the impact of nesiritide on length of hospital stay, readmission rates, and associated healthcare charges.

Main Methods:

• A structured retrospective chart review of 127 patients admitted with decompensated CHF.
• Data collected included initial length of stay, 3-month readmission rates, 3-month mortality, and pharmacy/hospital charges.
• Analysis stratified by ejection fraction (>30% vs. <=30%).

Main Results:

• Nesiritide showed no significant effect on initial length of stay, readmission rates, or 3-month mortality.
• Patients with ejection fraction >30% experienced longer hospital stays with nesiritide.
• Nesiritide treatment resulted in significantly higher pharmacy and hospital charges.

Conclusions:

• Nesiritide does not improve key clinical outcomes like length of stay, readmissions, or mortality in CHF patients.
• The use of nesiritide is associated with substantially increased healthcare costs.
• Further pharmacoeconomic analyses are needed to guide nesiritide's role in CHF management.